Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
Links relacionados
- Similares en SciELO
Compartir
Medicina (Buenos Aires)
versión impresa ISSN 0025-7680
Resumen
SEOANE, Leonardo; BARANCHUK, Adrián y CONDE, Diego. Vernakalant en la reversión de la fibrilación auricular de reciente comienzo. Medicina (B. Aires) [online]. 2015, vol.75, n.4, pp.239-244. ISSN 0025-7680.
Atrial fibrillation (AF) is the most common sustained arrhythmia. Cardioversion is considered one of the best treatments for recent onset AF, especially with drugs for avoiding sedation. Vernakalant is a novel antiarrhythmic that acts selectively in the atrium, and inhibits potassium currents, with minor blockade of IKr currents in the ventricle. It has been recently approved for pharmacological cardioversion of recent-onset AF in the European Union. The aim of this review is to analyze the pharmacokinetic and pharmacodynamic of vernakalant, and to show the efficacy and safety of this drug for the conversion of AF to sinus rhythm.
Palabras clave : Vernakalant; Recent-onset atrial fibrillation; Ion channels; Pharmacological cardioversion.